Lipella Pharmaceuticals Inc Revenue Growth Rates (LIPO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lipella Pharmaceuticals Inc   (LIPO)
 

LIPO's Revenue Growth by Quarter and Year

Lipella Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LIPO Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.09
1st Quarter March 0.13
FY 0.22





LIPO Revenue third quarter 2025 Y/Y Growth Comment
Lipella Pharmaceuticals Inc in the third quarter 2025 recorded of $ 0.00 millions.

According to the results reported in the third quarter 2025, Lipella Pharmaceuticals Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Lipella Pharmaceuticals Inc ' s Revenue meltdown of -100% ranks overall at the positon no. in the third quarter 2025.


LIPO Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 41.67 % -20 % -
3rd Quarter September - -20 % - -
2nd Quarter June -35.71 % 27.27 % - -
1st Quarter March -13.33 % 25 % 300 % -
FY   - 20 % 150 % -

Financial Statements
Lipella Pharmaceuticals Inc 's third quarter 2025 Revenue $ 0.00 millions LIPO's Income Statement
Lipella Pharmaceuticals Inc 's third quarter 2024 Revenue $ 0.08 millions Quarterly LIPO's Income Statement


LIPO Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 112.5 % 20 % -
3rd Quarter September - -42.86 % -9.09 % -
2nd Quarter June -30.77 % -6.67 % -8.33 % -
1st Quarter March -23.53 % 25 % -20 % -
FY (Year on Year)   - 20 % 150 % -


Back to LIPO Growth rate Comparisons >> Back to LIPO Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2024)   (Jun 30 2025)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2024)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Lipella Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LIPO's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Lipella Pharmaceuticals Inc come out even worse considering the 0.09 millions a quarter before.

Within Major Pharmaceutical Preparations industry Lipella Pharmaceuticals Inc achieved highest sequential Revenue growth. While Lipella Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LIPO's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Lipella Pharmaceuticals Inc come out even worse considering the 0.09 millions a quarter before.

Within Major Pharmaceutical Preparations industry Lipella Pharmaceuticals Inc achieved highest sequential Revenue growth. While Lipella Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is .


Lipella Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.47 $ 0.52 $ 0.54 $ 0.48
Y / Y Revenue Growth (TTM) - -7.3 % 8.88 % 19.29 % 0.78 %
Year on Year Revenue Growth Overall Ranking # 647 # 592 # 578 # 552 # 0
Seqeuential Revenue Change (TTM) - -9.56 % -3.07 % 10.92 % -4.67 %
Seq. Revenue Growth (TTM) Overall Ranking # 2503 # 1408 # 1446 # 1341 # 1150


Cumulative Revenue growth Comment
Lipella Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2025, compare to Revenue of $ 0 millions a year ago.

In the Healthcare sector 143 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 592 to 647.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 144
Overall # 647

Revenue TTM Y/Y Growth Statistics
High Average Low
19.29 %
 6.96 %
-7.3 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 114
Sector # 352
S&P 500 # 2503
Cumulative Revenue growth Comment
Lipella Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2025, compare to Revenue of $ 0 millions a year ago.

In the Healthcare sector 143 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 592 to 647.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 144
Overall # 647

Revenue TTM Y/Y Growth Statistics
High Average Low
19.29 %
6.96 %
-7.3 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LIPO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Community Health Systems Inc -0.10%$ -0.097 millions
Bioventus Inc -0.23%$ -0.232 millions
Bruker Corporation-0.39%$ -0.394 millions
Charles River Laboratories International inc -0.49%$ -0.486 millions
Protalix Biotherapeutics inc -0.60%$ -0.601 millions
Jaguar Health Inc -0.80%$ -0.804 millions
Bio techne Corp-1.01%$ -1.005 millions
Agilon Health Inc -1.08%$ -1.076 millions
Picard Medical Inc -1.25%$ -1.249 millions
Nexgel Inc -1.71%$ -1.709 millions
Capsovision Inc -1.75%$ -1.753 millions
Utah Medical Products Inc-2.02%$ -2.020 millions
10x Genomics Inc -2.04%$ -2.038 millions
Hyperfine Inc -2.06%$ -2.063 millions
Teladoc Health Inc -2.20%$ -2.197 millions
Lineage Cell Therapeutics Inc -2.59%$ -2.593 millions
Pacific Biosciences Of California Inc -2.83%$ -2.828 millions
Pluri Inc -3.07%$ -3.067 millions
Castle Biosciences Inc -3.19%$ -3.193 millions
Bionexus Gene Lab Corp -3.29%$ -3.291 millions
Nrc Health-3.38%$ -3.381 millions
Prestige Consumer Healthcare Inc -3.46%$ -3.459 millions
Sight Sciences Inc -3.57%$ -3.567 millions
Pediatrix Medical Group Inc -3.58%$ -3.577 millions
Quidelortho Corp-3.74%$ -3.741 millions
Escalon Medical Corp -3.81%$ -3.813 millions
Myriad Genetics Inc -3.98%$ -3.985 millions
Plus Therapeutics Inc -4.05%$ -4.052 millions
Perrigo Company Plc-4.07%$ -4.074 millions
P3 Health Partners Inc -4.66%$ -4.659 millions


About Lipella Pharmaceuticals Inc Revenue Growth Rates (LIPO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lipella Pharmaceuticals Inc (CIK 1347242).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001753926-25-001805
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lipella Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.